HDA President and CEO Chester “Chip” Davis, Jr., released the following statement on the U.S. Food and Drug Administration’s (FDA) decision to grant Emergency Use Authorization of the first COVID-19 vaccine, manufactured by Pfizer and BioNTech.
New data released today by the HDA Research Foundation illustrate the continued supply chain efficiencies generated by HDA-member specialty distributors. According to the latest edition of Specialty Pharmaceutical Distribution: Facts, Figures and Trends, specialty distributors are a vital nexus between 176 manufacturers and more than 49,000 provider ship-to points for administration or dispensing to patients.
Allied Against Opioid Abuse (AAOA) and the National Hispanic Medical Association (NHMA) released a new suite of resources to help educate the Hispanic community about the rights, risks and responsibilities associated with prescription opioids. The toolkit was developed by an advisory committee of NHMA members and features resources available in both Spanish and English.
Data published today by the HDA Research Foundation reveal an estimated 93 percent of all U.S. pharmaceutical sales were completed through HDA-member traditional pharmaceutical distributors in 2019. As illustrated in the 91st Edition HDA Factbook, total distributor sales reached $519 billion.
HDA President and CEO Chester “Chip” Davis, Jr., released the following statement on the announcement by the Department of Health and Human Services (HHS) of an interim final rule to implement a “Most Favored Nation Model” for Medicare Part B and a final rule eliminating the prescription drug rebate system for Medicare Part D.
